Keros Therapeutics reported a net loss of $23.5 million for the fourth quarter of 2025, a sharp improvement from the $46.0 million loss in the same period a year earlier. For the full year, the company posted a net income of $87.0 million, a turnaround from the $187.4 million loss recorded in 2024. Total revenue for 2025 reached $244.1 million, up from $3.6 million in 2024, largely driven by the $200 million upfront payment received from its licensing partnership with Takeda and subsequent milestone and royalty recognition.
The quarter’s revenue of $0.39 million fell short of analyst expectations by 94.08%, reflecting the timing of the Takeda license revenue. While the upfront payment was recognized in Q4, the bulk of the license revenue—future milestones and tiered royalties—will be recognized over time, resulting in a lower quarterly figure than projected. This revenue miss is offset by the company’s strong cash position and the fact that the licensing deal provides a non‑dilutive, long‑term revenue stream.
Keros cut costs aggressively, with research and development spending falling to $17.9 million in Q4 from $45.6 million a year earlier, and general and administrative expenses rising modestly to $11.7 million from $10.7 million. The company completed a 45 % workforce reduction and terminated its cibotercept program in early 2025, actions that helped bring operating expenses in line with the company’s leaner strategy. These measures contributed to the improved profitability and support the company’s goal of extending its cash runway into the first half of 2028.
Cash and cash equivalents stood at $287.4 million as of December 31 2025, down from $559.9 million a year earlier. The decline reflects a capital‑return program that included share repurchases and a tender offer. Despite the reduction, the remaining cash base is sufficient to fund the company’s pipeline and ongoing clinical activities through mid‑2028.
The company remains focused on advancing rinvatercept for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS). A Phase 2 trial of rinvatercept in DMD patients is slated to begin in Q2 2026. “The previous year was an important period of transition for the Company, during which we sharpened our strategic priorities. With that foundation in place, our attention is firmly on execution – advancing rinvatercept into a Phase 2 clinical trial in patients with Duchenne muscular dystrophy (“DMD”) and engaging regulators on the design of a Phase 2 clinical trial in patients with amyotrophic lateral sclerosis (“ALS”). With a strong foundation in place, our focus remains on bringing potential meaningful benefit to patients and creating long-term value for our stockholders.” – Jasbir S. Seehra, President and CEO.
Analysts had expected earnings per share of $-0.47; Keros reported $-0.86, a miss of 82.98%. Revenue expectations were also missed, with analysts projecting higher quarterly revenue. The miss underscores the company’s reliance on the Takeda licensing deal for revenue, which is recognized over time, and highlights the importance of the company’s cost‑control measures and pipeline progress in sustaining profitability moving forward.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.